Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 14/20 | 0.59 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3865235 | 0.90 | F10 (0.72) | F10CDK2 | |
| SCHEMBL3864158 | 0.90 | F10 (0.72) | F10CDK2MAPTLMNA | |
| SCHEMBL3866715 | 0.81 | F10 (0.88) | F10CDK2 | |
| SCHEMBL1675749 | 0.80 | F10 (0.49) | F10CDK2 | |
| SCHEMBL3872206 | 0.79 | F10 (0.61) | F10SMN1; SMN2L3MBTL1MAPTLMNA | |
| SCHEMBL3861689 | 0.79 | F10 (0.69) | F10SMN1; SMN2MAPTLMNA | |
| SCHEMBL3864135 | 0.79 | F10 (0.65) | F10SMN1; SMN2L3MBTL1MAPTLMNA | |
| SCHEMBL3866098 | 0.79 | F10 (0.88) | F10CDK2 | |
| SCHEMBL3864977 | 0.79 | F10 (0.73) | F10 | |
| SCHEMBL3865078 | 0.79 | F10 (0.88) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566789-B2 | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2009-07-28 | — | — | US | claimed |
| EP-1558247-B1 | BENZIMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-02-20 | — | — | EP | claimed |
| US-20050272740-A1 | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2005-12-08 | — | — | US | claimed |
| CN-1674893-A | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2005-09-28 | — | — | CN | claimed |
| US-7566789-B2 | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2009-07-28 | — | — | US | disclosed |
| EP-1558247-B1 | BENZIMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-02-20 | — | — | EP | disclosed |
| US-20050272740-A1 | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2005-12-08 | — | — | US | disclosed |
| CN-1674893-A | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2005-09-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272740-A1 | Benzimidazole derivatives | F12, F11, SERPINC1 | F10 5/4885CDK2 193/4885SMN1; SMN2 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.